Mangalam Drugs And Organics DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.90×	0.91×	1.40×	0.82×
	1.58×	1.47×	0.25×	−4.03×
	−11.5%	−14.3%	6.0%	0.7%
	0.68×	0.68×	0.91×	1.06×
	3.06×	3.06×	2.46×	2.46×
	−34.2%	−39.8%	4.7%	−6.4%
	−35.2%	−35.2%	4.7%	−6.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MANGALAM₹29.22

Mangalam Drugs And Organics Limited

· Pharma & Health

₹ CrorePeersBIOFILCHEM LASA VINEETLAB ORTINGLOBE KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹46.3 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	—	0.82	1.40	0.91	0.90
Interest Burden (Pretax/EBIT) ×	—	-4.03	0.25	1.47	1.58
EBIT Margin %	—	0.74	6.04	-14.27	-11.54
Asset Turnover ×	—	1.06	0.91	0.68	0.68
Financial Leverage (Assets/Equity) ×	—	2.46	2.46	3.06	3.06
ROE (5-step product, year-end total equity) %	—	-6.41	4.73	-39.75	-34.19
ROE (owners' profit / average owners' equity) %	—	-6.31	4.72	-35.23	-35.23

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.